123770-62-7

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLATE is used as an intermediate in the synthesis of pharmaceuticals for its potential anti-inflammatory and anti-cancer properties. Its ability to be modified for enhanced biological activity makes it a valuable component in the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 5-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLATE is utilized as a building block in the creation of agrochemicals, potentially contributing to the development of new pesticides or other agricultural chemicals that can improve crop protection and yield.
Used in Drug Discovery and Development:
ETHYL 5-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLATE is employed as a target for drug discovery and development due to its potential medicinal properties. Researchers can modify its structure to create new compounds with improved therapeutic effects, broadening the scope of treatment options for various diseases and conditions.

Upstream product

• 107-19-7 propargyl alcohol 
• 626-35-7 nitroacetic acid ethyl ester 
• 861135-87-7 chlorohydroxyimino-acetic acid ethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 
• 95080-93-6 ethyl chlorooximidoacetate 
• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 

Downstream Products

• 139297-56-6 5-(hydroxymethyl)-1,2-oxazole-3-carboxylic acid 
• 22667-24-9 ethyl 5-formylisoxazole-3-carboxylate 
• 875489-11-5 toluene-4-sulfonic acid 3-tert-butyl-7-(5-hydroxymethyl-isoxazol-3-yl)-pyrazolo[1,5-d][1,2,4]triazin-2-yl ester 
• 833445-84-4 3-allyloxycarbonyl-5-bromomethylisoxazole 
• 145441-16-3 5-fluoromethyl-3-isoxazolecarboxylic acid 
• 139297-37-3 N-(2,6-dimethylphenyl)-5-benzoyloxymethyl-3-isoxazolecarboxamide 
• 130403-18-8 D₃₀₁₇ 
• 139297-39-5 N-(2,6-dimethylphenyl)-5-fluoromethyl-3-isoxazolecarboxamide 
• 1208428-03-8 (5-hydroxymethyl-isoxazol-3-yl)-diphenyl-methanol 
• 84654-29-5 5-(bromomethyl)-3-isoxazolecarboxylic acid ethyl ester 
• 133674-44-9 3-(ethoxycarbonyl)isoxazole-5-carboxylic acid 
• 1332461-50-3 (Z)-3-((5-((4-(3-methoxyphenyl)piperazin-1-yl)methyl)iso-xazol-3-yl)methylene)indolin-2-one 
• 1332461-51-4 (E)-3-((5-((4-m-tolylpiperazin-1-yl)methyl)isoxazol-3-yl)-methylene)indolin-2-one 
• 1332461-52-5 (Z)-3-((5-((4-m-tolylpiperazin-1-yl)methyl)isoxazol-3-yl)-methylene)indolin-2-one 

Relevant academic research and scientific papers

Synthesis and Characterization of Isoxazole-Based Energetic Plasticizer Candidates EEIN and IDN

This study presents the synthesis of ethyl 5-[(nitrooxy)methyl]isoxazole-3-carboxylate (EEIN) and isoxazole-3,5-diylbis(methylene) dinitrate (IDN). These compounds, each derived from 5-(hydroxymethyl)isoxazole-3-carboxylate, were fully characterized and their explosive sensitivity properties were determined. EEIN was isolated as a solid material with a relatively low melting temperature and IDN was isolated as a liquid with excellent energetic performance properties. In addition, we report the molecular structure of ethyl 5-[(nitrooxy)methyl]isoxazole-3-carboxylate as determined by single-crystal X-ray diffractometry. These compounds possess promising properties as plasticizing ingredients in propellant formulations.

Novel 1β-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt

The synthesis of novel 1β-methylcarbapenems 1a,b having sodium 5-(3- and 5-carboxylic acid)isoxazoloethenyl moieties at C-5 position of pyrrolidine ring and their biological evaluation are described. Both compounds showed potent and well-balanced antibacterial activity as well as high stability to DHP-I. The selected sodium 3-carboxylic acid derivative 1a possessed excellent DHP-I stability and advanced pharmacokinetic parameters in comparison with 2 and meropenem. The synthesis of novel 1β-methylcarbapenems 1a,b having sodium 5-(3- and 5-carboxylic acid)isoxazoloethenyl moieties at C-5 position of pyrrolidine ring and their biological evaluation are described. Both compounds showed potent and well-balanced antibacterial activity as well as high stability to DHP-I. The selected sodium 3-carboxylic acid derivative 1a possessed excellent DHP-I stability and advanced pharmacokinetic parameters in comparison with 2 and meropenem.

Catalyst-free formation of nitrile oxides and their further transformations to diverse heterocycles

The formation of nitrile oxides with diazocarbonyl compounds by nitrosyl transfer from tert-butyl nitrite under mild conditions and without the use of a catalyst or an additive is reported. This transformation is broadly applicable to the synthesis of fur

SMALL MOLECULES INHIBITING TDP-43 ACTIVITY AND USES THEREOF

The present invention relates to the field of medical pharmacology. In particular, the present invention relates to pharmaceutical agents that serve as inhibitors of the activity of TDP-43. The invention further relates to methods of treatment and / or alleviation of symptoms related to pathological conditions associated with the activity of TDP-43 (for example, neurodevelopmental disorders), comprising the administration to a subject (for example, a human patient) of a composition comprising one or more pharmaceutical agents serving as inhibitors of the activity of TDP-43.

MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS

Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

Synthesis of 5-(Fluoroalkyl)isoxazole Building Blocks by Regioselective Reactions of Functionalized Halogenoximes

A comprehensive study on the synthesis of 5-fluoroalkyl-substituted isoxazoles starting from functionalized halogenoximes is reported. One-pot metal-free [3 + 2] cycloaddition of CF3-substituted alkenes and halogenoximes bearing ester, bromo, c